Intensity raised over $20 million in 2025 through equity offerings and held $11.9 million in cash and equivalents as of December 31, 2025, extending its operating runway into the second quarter of 2027. Research and development expenses declined to $6.8 million from $10.5 million in 2024.

In the Phase 2 INVINCIBLE-4 trial for early-stage operable triple negative breast cancer, 71.4% of patients receiving INT230-6 before standard of care achieved pathological complete response versus 33% in the control arm, with 44% fewer grade 3 or higher adverse events. Full enrollment resumed in Switzerland on March 26, 2026, following regulatory approval.

The Phase 1/2 IT-01 study demonstrated a 75% disease control rate and median overall survival of 11.9 months in 64 refractory metastatic cancer patients, with a 21.3-month median survival in a sarcoma subset. Patients treated on over 40% of their tumor burden saw an 83.3% disease control rate, 18.7-month median survival and notable abscopal responses, with no dose-limiting toxicities reported.

The Phase 3 INVINCIBLE-3 trial in second- and third-line soft tissue sarcoma paused new site activations in March 2025 due to funding constraints after enrolling 21 patients. The company continues patient treatment and data management at reduced cost, aiming to resume enrollment in 2026 once additional funding is secured.